Viralym-M, a T cell product, treats up to 5 different viral infections

Discussion in 'Antivirals and Immune Health' started by Remy, Jul 18, 2018.

  1. Remy

    Remy Administrator

    HOUSTON, Aug. 22, 2017 /PRNewswire/ -- ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M. The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1.